Celyad scraps one final clinical CAR-T program as clock ticks
Celyad Oncology began the year with hopes that it could garner the first evidence that its off-the-shelf CAR-T approach could lead to much-needed breakthroughs in solid tumors. But patient deaths derailed those plans and, as cash dwindled and partnership talks went nowhere, the French biotech went into survival mode, selling its manufacturing site and pausing clinical programs.
The last one standing is now gone, too.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
